Analysis of safety from a human clinical trial with pterostilbene

Journal of Toxicology

Volumn 2013, Issue , 2013, Pages

  Riche, Daniel M ^a,b   McEwen, Corey L ^c   Riche, Krista D ^a,d   Sherman, Justin J ^a   Wofford, Marion R ^b   Deschamp, David ^b   Griswold, Michael ^b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d St Dominic Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GLUCOSE; GRAPEFRUIT EXTRACT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PTEROSTILBENE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANALYSIS; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SIDE EFFECT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

EID: 84874620782     PISSN: 16878191     EISSN: 16878205     Source Type: Journal    
DOI: 10.1155/2013/463595     Document Type: Article

References (16)

1. Ferrières J., The French paradox: lessons for other countries. Heart 2004 90 1 107 111 2-s2.0-0346059361 (Pubitemid 38064560)
2. Das D. K., Sato M., Ray P. S., Maulik G., Engelman R. M., Bertelli A. A. E., Bertelli A., Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs under Experimental and Clinical Research 1999 25 2-3 115 120 2-s2.0-0033034560 (Pubitemid 29257603)
3. Lin H. S., Yue B. D., Ho P. C., Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomedical Chromatography 2009 23 12 1308 1315 2-s2.0-71649110385 10.1002/bmc.1254
4. Kapetanovic I. M., Muzzio M., Huang Z., Thompson T. N., McCormick D. L., Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemotherapy and Pharmacology 2011 68 593 601
5. Asensi M., Medina I., Ortega A., Carretero J., Baño M. C., Obrador E., Estrela J. M., Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biology and Medicine 2002 33 3 387 398 2-s2.0-0036667553 10.1016/S0891-5849(02)00911-5 (Pubitemid 34786278)
6. Remsberg C. M., Yáñez J. A., Ohgami Y., Vega-Villa K. R., Rimando A. M., Davies N. M., Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytotherapy Research 2008 22 2 169 179 2-s2.0-40549119870 10.1002/ptr.2277 (Pubitemid 351363234)
7. Nutakul W., Sobers H. S., Qiu P., Dong P., Decker E. A., McClements D. J., Xiao H., Inhibitory effects of resveratrol and pterostilbene on human colon cancer cells: a side-by-side comparison. Journal of Agricultural and Food Chemistry 2011 59 20 10964 10970
8. Rimando A. M., Nagmani R., Feller D. R., Yokoyama W., Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor α -isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. Journal of Agricultural and Food Chemistry 2005 53 9 3403 3407 2-s2.0-19944410516 10.1021/jf0580364 (Pubitemid 40758174)
9. Pan Z., Agarwal A. K., Xu T., Feng Q., Baerson S. R., Duke S. O., Rimando A. M., Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol. BMC Medical Genomics 2008 1, article 7
10. Mizuno C. S., Ma G., Khan S., Patny A., Avery M. A., Rimando A. M., Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPAR α Bioorganic and Medicinal Chemistry 2008 16 7 3800 3808 2-s2.0-41649120931 10.1016/j.bmc.2008.01.051 (Pubitemid 351484033)
11. U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for industry: frequently asked questions about GRAS. 2011. http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/ GuidanceDocuments/FoodIngredientsandPackaging/ucm061846.htm
12. Hougee S., Faber J., Sanders A., De Jong R. B., Van Den Berg W. B., Garssen J., Hoijer M. A., Smit H. F., Selective COX-2 inhibition by a Pterocarpus marsupium extract characterized by pterostilbene, and its activity in healthy human volunteers. Planta Medica 2005 71 5 387 392 2-s2.0-20544470196 10.1055/s-2005-864130 (Pubitemid 40839768)
13. Gottumukkala V. S., Masna M., Hindupur R. M., Thatipally S., Inventors, aptuit laurus private limited, assignee. X. World patent WO, 2010/0101578 A2, 2009
14. Tsimihodimos V., Kakafika A., Elisaf M., Fibrate treatment can increase serum creatinine levels. Nephrology Dialysis Transplantation 2001 16 6, article 1301 2-s2.0-0034970314
15. McBride B. F., Karapanos A. K., Krudysz A., Kluger J., Coleman C. I., White C. M., Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. Journal of the American Medical Association 2004 291 2 216 221 2-s2.0-0345831912 10.1001/jama.291.2.216 (Pubitemid 38082816)
16. Henyan N. N., Riche D. M., Pitcock J. J., Strickland D. C., Marked transaminase elevations and worsening glycemic control associated with counterfeit polyherbal use in a patient with diabetes. Journal of Pharmacy Practice 2009 22 6 600 605 2-s2.0-77949400232 10.1177/0897190009341257